Octapharma's haemophilia prophylaxis performs well in comparison

09 November 2023 12:01

Greater Zurich

Supporting partner

Lachen - Nuwiq, for the personalized prophylaxis of bleeding in haemophilia A has shown significantly better results in an indirect comparison with other treatments. However, the weekly dose is higher for the drug developed by Octapharma from the canton of Schwyz.

Octapharma’s haemophilia drug Nuwiq has performed positively in an indirect comparative study. According to the results, personalized prophylaxis with Nuwiq can lead to a higher rate of patients without bleeding compared to other recombinant products that replace the missing coagulation factor FVIII. However, the drug requires higher weekly doses. The data were recently published in the “European Journal of Haematology”. Preliminary data were presented by Dr. Craig Kessler of the Lombardi Comprehensive Cancer Center and Georgetown University Medical Center at the 65th Annual Meeting of the American Society of Hematology.

According to a statement from Octapharma, the established statistical method of matching-adjusted indirect comparison (MAIC) was used for the study. The analysis compared the efficacy of Nuwiq with that of Eloctate, Jivi and Adynovate. It used data from prospective clinical studies on personalized prophylaxis in adults with severe haemophilia A.

Nuwiq was found to lead to a significantly higher percentage of patients without bleeding compared to Eloctate (75 to 45 per cent), Jivi (77 to 38 per cent) and Adynovate (78 to 42 per cent), with an FVIII target of 1 to 3 per cent. Nuwiq was similarly effective compared to Adynovate with an FVIII target of 8 to 12 per cent (77 to 62 per cent). The mean annualized bleeding rate was significantly lower with Nuwiq than with Jivi (1.5 versus 4.9). The weekly dose was higher for Nuwiq than for Eloctate, Jivi or Adynovate with target FVIII levels of 1 to 3 per cent, but lower than for Adynovate with target FVIII levels of 8 to 12 per cent. ce/mm

Supporting partner

Swiss Pavilion Digital